Slide 1: Harnessing the Human Memory B Cell Response To Develop Antibody-Based Therapeutics
Harnessing the Human Memory B Cell Response To Develop Antibody - Based Therapeutics September 21, 2021 Immunome, Inc. 665 Stockton Drive, Suite 300 | Exton, PA 19341 610.321.3700 | www.immunome.com Copyright © 2021 Immunome, Inc. All rights reserved.
Slide 2: Disclaimers and Forward-Looking Statements
2 Disclaimers and Forward - Looking Statements This presentation includes certain disclosures that contain “forward - looking statements” intended to qualify for the “safe harbor” from liability established by the Private Securities Litigation Reform Act of 1995, as amended, including, without limit
Slide 3: Experienced Management Team
Experienced Management Team Copyright © 2021 Immunome, Inc. All rights reserved. 3 Purnanand Sarma, PhD President & CEO Corleen Roche Chief Financial Officer Mike Morin, PhD Chief Scientist Sandra Stoneman, Esq. Chief Legal Officer Dennis Giesing, PhD Chief Development Officer Matthew Robinson, PhD
Slide 4: Immunome "At A Glance"
IMM - BCP - 01 Treatment of COVID - 19 • Three antibody cocktail • Binds to three non - overlapping regions of the spike protein • ACE2 and Non ACE2 dependent neutralization • Potent Effector Function – potential for viral clearance 4 Copyright © 2021 Immunome, Inc. All rights reserved. IMM - ONC -
Slide 5: Immunome Development Pipeline and Anticipated Key Milestones
Immunome Development Pipeline and Anticipated Key Milestones ANTI - INFECTIVES TARGET PRODUCT CANDIDATE DESCRIPTION DISCOVERY PRECLINICAL ANTICIPATED MILESTONE IMM - BCP - 01 Three SARS - CoV - 2 Epitopes Three antibody cocktail IND filing Q4 2021 ONCOLOGY TARGET PRODUCT CANDIDATE DESCRIPTION DISCOV
Slide 6: Proprietary Discovery Engine
6 Copyright © 2021 Immunome, Inc. All rights reserved. Proprietary Discovery Engine Memory B cells: The Most Educated Components of Human Immune System We see Disease Through the Lens of a B cell Antibody Screening Deep, multiplexed interrogation of patient memory B cell responses Patient Response C
Slide 7: Infectious Diseases Collaboration with U.S. DoD awarded up to $17.6M in funding
Infectious Diseases Copyright © 2021 Immunome, Inc. All rights reserved. Collaboration with U.S. DoD awarded up to $17.6M in funding
Slide 8: COVID-19 Summary
COVID - Summary Current COVID Vaccines and Antibody Therapeutics Not Sufficient • Breakthrough infections despite vaccine use 1 • FDA Emergency Use Authorization of antibody therapeutics for treatment of mild to moderate COVID - 19 2 • First - generation antibody therapeutics developed based on viru
Slide 9: COVID Vaccines Are Effective, But Not Sufficient
COVID - 19 Vaccines Are Effective, But Not Sufficient CDC Website Statistics (8/30/2021) • 173.8M people fully vaccinated » 52.4% fully vaccinated (61.3% of population >12) • However new variants driving resurgence of cases and deaths Pfizer Vaccine AstraZeneca Vaccine • Vaccines targeting original
Slide 10: U.S. COVID Surge Continues to Lead to Severe Disease
U.S. COVID Surge Continues to Lead to Severe Disease COVID Surges Despite >50% of U.S. Fully Vaccinated » Approximately 1,500 deaths per day » Cases driven by: • Vaccinated but high risk: • Elderly • Underlying conditions • Immunocompromised • Unvaccinated New Infections Deaths 7 - Day Average 7 - D
Slide 11: Israel Surging Despite Highest COVID-19 Vaccination Rate in the World
New Infections Deaths 11 Israel Surging Despite Highest COVID - 19 Vaccination Rate in the World Copyright © 2021 Immunome, Inc. All rights reserved. COVID - 19 Will Likely Remain Endemic & Specific Populations Will Continue to be at Risk 7 - Day Average Daily New Infections 2019 Source: www.ourworl
Slide 12: COVID Therapeutics Will Remain Critical
COVID - 19 Therapeutics Will Remain Critical Variants will likely continue to emerge, and may rapidly change the landscape » Delta variant encompasses >99% of all U.S. cases since discovery in April ‘21 » Eta, Iota, Kappa, and Lambda variants are a growing concern Evidence of decreased vaccine cover
Slide 13: Three Antibody Cocktail has Multiple Points of Attack and Multiple Mechanisms of Action
Three Antibody Cocktail has Multiple Points of Attack and Multiple Mechanisms of Action » Susceptible to viral escape, Lilly antibody temporarily withdrawn » Plateau of clinical benefit with escalated dose Based on our current beliefs/opinions about selected publicly available preclinical data for o
Slide 14: Immunome's Approach Optimized for Ideal Target Profile
Immunome’s Approach Optimized for Ideal Target Profile • Preclinical potency suggests efficacious dose may allow for non - Intravenous dosing • Preclinical evidence of ACE dependent and non - dependent action; three different epitopes. Synergy against variants of concern. Clearance by phagocytosis a
Slide 15: IMM-BCP-01: Mimics the Body's Natural Response
IMM - BCP - 01: Mimics the Body’s Natural Response Leverages Unique and Cryptic Epitopes EPITOPE 1: IMM20253 (Non - ACE2 Dependent) • Broadly conserved across all SARS - CoV - 2 strains and other Beta coronaviruses • Novel mechanism. Antibody exhibits non ACE2 dependent neutralization EPITOPE 2: IMM
Slide 16: IMM-BCP-01 Superior Preclinical Efficacy and Prophylactic Dose Response vs Sotrovimab
Sotrovimab (EUA Approved at 500 mg Dose) IMM - BCP - 01 16 Superior Preclinical Efficacy and Prophylactic Dose Response vs Sotrovimab Copyright © 2021 Immunome, Inc. All rights reserved. Cathcart , A.L et al BioRxiv 2021.03.09.434607 WT Strain • Prophylactic setting (Day - 2) in infected hamsters •
Slide 17: IMM-BCP-01 Neutralizes all CDC Variants of Concern in Pseudovirus Testing
Copyright © 2021 Immunome, Inc. All rights reserved. 17 IMM - BCP - 01 Neutralizes all CDC Variants of Concern in Pseudovirus Testing • Alpha, Beta, Gamma, Delta » CDC Variants of Concern (as of 09/20/2021) • Emerging Variants » Delta Plus, Lambda • US and European reference strains, USA - WA1/2020
Slide 18: Viral Clearance is Important, Especially in Immunocompromised Patients
• Immunocompromised patients exhibit prolonged viral load • Prolonged infection leads to emerging resistant variants Viral Clearance is Important, Especially in Immunocompromised Patients Caillard , S., Benotmane , I., Vargas, G. G., Perrin, P., & Fafi - Kremer, S. (2021). SARS - CoV - 2 viral dynam
Slide 19: IMM-BCP-01 Clinical Development Plan
3 5 IND Filing Q4 2021 Phase 1b FIP Study Dose Ranging • Placebo - controlled • Safety, PK, Immunogenicity Potential Phase 1b Extension in Special Population • Treatment and prophylaxis • Safety, PK, viral load Phase 2 Potential Registration Study H2 2022 Copyright © 2021 Immunome, Inc. All rights r
Slide 20: COVID Antibody Market
COVID Antibody Market REGENERON $2.6B IN 2Q 2021 ADAGIO $3 - 4B ANALYST PROJECTED PEAK SALES * Addressable Patients • High Risk Vaccinated Patients with Breakthrough Infection • High Risk Unvaccinated Patients • Immunocompromised Patients (~9M in the US), Including: » Transplant » HIV » Chemotherapy
Slide 21: Oncology Research & Development
Oncology • RESEARCH & DEVELOPMENT Copyright © 2021 Immunome, Inc. All rights reserved.
Slide 22: Oncology Summary
Oncology - Summary Highly disruptive platform discovering novel targets based on function - based interrogation of patient memory B - cell response to tumors • Broad, deep and unbiased interrogation • Operating at industrial scale; ~1300 hits, >50 novel targets/antibodies to - date • Platform highli
Slide 23: Novel Targets: Antibodies From Patient Memory B-cells Can Reveal Novel Therapeutic Targets
Novel Targets Antibodies From Patient Memory B - cells Can Reveal Novel Therapeutic Targets Tumor Tumor killing Tumor Antigen Immune Response Antibody Control Exosome T cells activation Angiogenesis Metabolism Recruitment Mutation Post - translational modification Mis - localization Oncovirus Myeloi
Slide 24: Novel Insights from Discovery Engine
24 Novel Insights from Discovery Engine 1. Adv Clin Chem. 2016;74:103 - 41.DOI: 10.1016/bs.acc.2015.12.005 2. Mol Cancer. 2019 Oct 23;18(1):146. doi : 10.1186/s12943 - 019 - 1074 - 3 3. Including some commercially - validated targets such as ERBB2 Provides Critical Insights Into Cancer Biology Such
Slide 25: Immunome Oncology R&D Pipeline
Immunome Oncology R&D Pipeline Targets Identified From Patient Antibodies Program Novel Immune Modulators Potential Cancers of Relevance Stage/Format IMM - ONC - 01 (Anti - IL - 38) Neutralize apoptotic tumor cells derived IL - 38; recruit and activate immune cells Lung, head and neck, melanoma, and
Slide 26: IL-38: A Novel Oncology Target
IL - 38: A Novel Oncology Target IL - 38 Dampens Innate Anti - Tumor Immunity • IL - 38 is an IL - 1 cytokine family member, but most closely resembles the natural antagonists of the family (IL - 1Ra and IL - 36a) ANTAGONISTS AGONISTS IL36 a IL36 b IL36 g IL36Ra IL38 Autoimmunity Immune Suppression
Slide 27: Clinical Consequences of IL-38 Expression
• IL - 38 secretion associated with apoptotic cell death 1 • Acts during tissue damage to limit unwanted immune activation 2 • Tumor cells secrete IL - 38 during apoptosis in vitro • Rational combination with chemotherapies that induce apoptosis in tumors Clinical Consequences of IL - 38 Expression
Slide 28: IL-38 is Expressed in Multiple Tumors of High Unmet Medical Need
IL - 38 is Expressed in Multiple Tumors of High Unmet Medical Need Immunome Data - IL - 38 Expression in Primary Patient Tumors Confirmed by IHC IL - 38 Expression in Solid Tumors IL - 38 is expressed in Multiple Tumors of High Unmet Medical Need Head & Neck Lung, Squamous Esophagus Cervix Prostate
Slide 29: Blocking IL-38 Leads to Tumor Control in Two Different Tumor Models
Demonstration of Anti - Tumor Activity (B16F10 Model) Induction of Anti - Tumor Memory (EMT6 Model) • Immunologically cold tumor model • IMM - ONC - 01 equivalent to best in class I/O (anti - CTLA4) in this model • ~40% response rate upon treatment with IMM - ONC - 01 • Animals with complete cures r
Slide 30: IMM-ONC-01 is a Novel Antibody Candidate Targeting IL-38
• IL - 38 is a novel checkpoint in the innate immune system • Targeting IL - 38 using IMM - ONC - 01 expected to boost anti - tumor immunity • Preclinical research confirms the mechanism of action, and demonstrates efficacy, even as a monotherapy » Potential indications include lung, head and neck,
Slide 31: Immunome "At A Glance"
IMM - BCP - 01 Treatment of COVID - 19 • Three antibody cocktail • Binds to three non - overlapping regions of the spike protein • ACE2 and Non ACE2 dependent neutralization • Potent Effector Function – potential for viral clearance 31 Copyright © 2021 Immunome, Inc. All rights reserved. IMM - ONC -
Slide 32: Thank You
Thank You September 21, 2021 Immunome, Inc. 665 Stockton Drive, Suite 300 | Exton, PA 19341 610.321.3700 | www.immunome.com